global glp-1 obesity drug market size forecast 2030 The Therapeutics Market: Transforming a Major Health Challenge into a Pharmaceutical Megatrend The Obesity Drug Boom

JAMA Health Forum

[DOI] [PMC free article] [PubMed] 61.Novo Nordisk A/S

Future Warnings Alison Cave, Chief Safety Officer of the MHRA, said: For the vast majority of patients who are prescribed GLP-1s, they are safe and effective medicines which deliver significant health benefits

Occup Environ Med

Increasing BMI has been correlated with higher mortality risks, including a 29% rise in overall mortality and over a 200% increase in diabetes-related mortality for every 5-unit BMI increase above 25 kg/m (4)

Pharmaceutical companies are aggressively investing in research and development, expanding the diabetes drug pipeline with novel therapies designed to manage blood sugar levels and promote weight loss